Market Research Logo

Transplantation Drug Development Pipeline Review, 2017

Transplantation Drug Development Pipeline Review, 2017

Summary


This report provides an overview of the transplantation pipeline landscape, specifically covering drugs used to prevent and treat organ rejection and graft-versus-host disease. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), and the rejection of bone, liver, kidney, lung and heart transplants.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. There are a total of 121 products in development for this indication, by 83 companies and 21 academic institutions. Key companies operating in this pipeline space include Novartis and Abbvie.

GVHD is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. There are a total of 108 products in development for this indication, by 76 companies and 19 academic institutions. Similarly to the bone marrow transplantation space, key companies operating in this pipeline space include Novartis and Abbvie.

Following a liver transplant, the immune system may consider the transplanted liver as foreign and may work against it. Patients may hence develop complications and ultimately reject the new organ. There are a total of ten products in development for this indication, by seven companies and two academic institutions.

Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. There are a total of 39 products in development for this indication, by 33 companies and two academic institutions. Key companies operating in this pipeline space include Astellas, GlaxoSmithKline, Hillhurst Biopharmaceuticals and Kyowa Hakko Kirin.

Lung transplantation is a therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. There are a total of ten products in development for this indication, by eight companies. Key companies operating in this pipeline space include Quark Pharmaceuticals and Radikal Therapeutics, both of which are fielding two products in this area each.

Finally, heart transplantation is a therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted heart as foreign and may work against it. There are a total of seven products in development for this indication, all of which are in the Preclinical stage, by five companies, Of these products, Astellas are fielding three.

A wide range of targets, including integrins, chemokine receptors, protein kinases and cadherins are being developed, with no particular class of target predominating in terms of pipeline volume. However, there is a clear trend towards immune system molecular targets being studied, reflecting the underlying immune-based pathophysiology of these indications.Scope

  • Which companies are the most active within the pipeline for transplantation therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of transplantation therapeutics?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Transplantation Report Coverage
    • Bone Marrow Transplant Rejection – Overview
    • Graft Versus Host Disease (GVHD) –Overview
    • Liver Transplant Rejection – Overview
    • Kidney Transplant Rejection – Overview
    • Lung Transplant Rejection – Overview
    • Heart Transplant Rejection – Overview
  • Therapeutics Development
    • Bone Marrow Transplant Rejection
      • Pipeline Overview
        • Table Figure 1: Number of Products under Development for Bone Marrow Transplant Rejection
        • Table Number of Products under Development for Bone Marrow Transplant Rejection
      • Pipeline by Companies
        • Table Figure 2: Number of Products under Development by Companies, Bone Marrow Transplant Rejection
        • Table Number of Products under Development by Companies, Bone Marrow Transplant Rejection
      • Pipeline by Universities/Institutes
        • Table Figure 3: Number of Products under Development by Universities/Institutes, Bone Marrow Transplant Rejection
        • Table Number of Products under Development by Universities/Institutes, Bone Marrow Transplant Rejection
      • Products under Development by Companies
        • Table Products under Development by Companies, Bone Marrow Transplant Rejection
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Bone Marrow Transplant Rejection
    • Graft Versus Host Disease (GVHD)
      • Pipeline Overview
        • Table Figure 4: Number of Products under Development for Graft Versus Host Disease (GVHD)
        • Table Number of Products under Development for Graft Versus Host Disease (GVHD)
      • Pipeline by Companies
        • Table Figure 5: Number of Products under Development by Companies, Graft Versus Host Disease (GVHD)
        • Table Number of Products under Development by Companies, Graft Versus Host Disease (GVHD)
      • Pipeline by Universities/Institutes
        • Table Figure 6: Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)
        • Table Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)
      • Products under Development by Companies
        • Table Products under Development by Companies, Graft Versus Host Disease (GVHD)
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)
    • Liver Transplant Rejection
      • Pipeline Overview
        • Table Figure 7: Number of Products under Development for Liver Transplant Rejection
        • Table Number of Products under Development for Liver Transplant Rejection
      • Pipeline by Companies
        • Table Figure 8: Number of Products under Development by Companies, Liver Transplant Rejection
        • Table Number of Products under Development by Companies, Liver Transplant Rejection
      • Pipeline by Universities/Institutes
        • Table Figure 9: Number of Products under Development by Universities/Institutes, Liver Transplant Rejection
        • Table Number of Products under Development by Universities/Institutes, Liver Transplant Rejection
      • Products under Development by Companies
        • Table Products under Development by Companies, Liver Transplant Rejection
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Liver Transplant Rejection
    • Kidney Transplant Rejection
      • Pipeline Overview
        • Table Figure 10: Number of Products under Development for Kidney Transplant Rejection
        • Table Number of Products under Development for Kidney Transplant Rejection
      • Pipeline by Companies
        • Table Figure 11: Number of Products under Development by Companies, Kidney Transplant Rejection
        • Table Number of Products under Development by Companies, Kidney Transplant Rejection
      • Pipeline by Universities/Institutes
        • Table Figure 12: Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection
        • Table Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection
      • Products under Development by Companies
        • Table Products under Development by Companies, Kidney Transplant Rejection
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Kidney Transplant Rejection
    • Lung Transplant Rejection
      • Pipeline Overview
        • Table Figure 13: Number of Products under Development for Lung Transplant Rejection
        • Table Number of Products under Development for Lung Transplant Rejection
      • Pipeline by Companies
        • Table Figure 14: Number of Products under Development by Companies, Lung Transplant Rejection
        • Table Number of Products under Development by Companies, Lung Transplant Rejection
      • Products under Development by Companies
        • Table Products under Development by Companies, Lung Transplant Rejection
    • Heart Transplant Rejection
      • Pipeline Overview
        • Table Number of Products under Development for Heart Transplant Rejection
      • Pipeline by Companies
        • Table Number of Products under Development by Companies, Heart Transplant Rejection
      • Products under Development by Companies
        • Table Products under Development by Companies, Heart Transplant Rejection
  • Therapeutics Assessment
    • Bone Marrow Transplant Rejection
      • Assessment by Target
        • Table Figure 15: Number of Products by Top 10 Targets, Bone Marrow Transplant Rejection
        • Table Figure 16: Number of Products by Stage and Top 10 Targets, Bone Marrow Transplant Rejection
        • Table Number of Products by Stage and Target, Bone Marrow Transplant Rejection
      • Assessment by Mechanism of Action
        • Table Figure 17: Number of Products by Top 10 Mechanism of Actions, Bone Marrow Transplant Rejection
        • Table Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions, Bone Marrow Transplant Rejection
        • Table Number of Products by Stage and Mechanism of Action, Bone Marrow Transplant Rejection
      • Assessment by Route of Administration
        • Table Figure 19: Number of Products by Routes of Administration, Bone Marrow Transplant Rejection
        • Table Figure 20: Number of Products by Stage and Routes of Administration, Bone Marrow Transplant Rejection
        • Table Number of Products by Stage and Route of Administration, Bone Marrow Transplant Rejection
      • Assessment by Molecule Type
        • Table Figure 21: Number of Products by Top 10 Molecule Types, Bone Marrow Transplant Rejection
        • Table Figure 22: Number of Products by Stage and Top 10 Molecule Types, Bone Marrow Transplant Rejection
        • Table Number of Products by Stage and Molecule Type, Bone Marrow Transplant Rejection
    • Graft Versus Host Disease (GVHD)
      • Assessment by Target
        • Table Figure 23: Number of Products by Top 10 Targets, Graft Versus Host Disease (GVHD)
        • Table Figure 24: Number of Products by Stage and Top 10 Targets, Graft Versus Host Disease (GVHD)
        • Table Number of Products by Stage and Target, Graft Versus Host Disease (GVHD)
      • Assessment by Mechanism of Action
        • Table Figure 25: Number of Products by Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD)
        • Table Figure 26: Number of Products by Stage and Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD)
        • Table Number of Products by Stage and Mechanism of Action, Graft Versus Host Disease (GVHD)
      • Assessment by Route of Administration
        • Table Figure 27: Number of Products by Routes of Administration, Graft Versus Host Disease (GVHD)
        • Table Figure 28: Number of Products by Stage and Routes of Administration, Graft Versus Host Disease (GVHD)
        • Table Number of Products by Stage and Route of Administration, Graft Versus Host Disease (GVHD)
      • Assessment by Molecule Type
        • Table Figure 29: Number of Products by Top 10 Molecule Types, Graft Versus Host Disease (GVHD)
        • Table Figure 30: Number of Products by Stage and Top 10 Molecule Types, Graft Versus Host Disease (GVHD)
        • Table Number of Products by Stage and Molecule Type, Graft Versus Host Disease (GVHD)
    • Liver Transplant Rejection
      • Assessment by Target
        • Table Figure 31: Number of Products by Top 10 Targets, Liver Transplant Rejection
        • Table Figure 32: Number of Products by Stage and Top 10 Targets, Liver Transplant Rejection
        • Table Number of Products by Stage and Target, Liver Transplant Rejection
      • Assessment by Mechanism of Action
        • Table Figure 33: Number of Products by Top 10 Mechanism of Actions, Liver Transplant Rejection
        • Table Figure 34: Number of Products by Stage and Top 10 Mechanism of Actions, Liver Transplant Rejection
        • Table Number of Products by Stage and Mechanism of Action, Liver Transplant Rejection
      • Assessment by Route of Administration
        • Table Figure 35: Number of Products by Routes of Administration, Liver Transplant Rejection
        • Table Figure 36: Number of Products by Stage and Routes of Administration, Liver Transplant Rejection
        • Table Number of Products by Stage and Route of Administration, Liver Transplant Rejection
      • Assessment by Molecule Type
        • Table Figure 37: Number of Products by Molecule Types, Liver Transplant Rejection
        • Table Figure 38: Number of Products by Stage and Molecule Types, Liver Transplant Rejection
        • Table Number of Products by Stage and Molecule Type, Liver Transplant Rejection
    • Kidney Transplant Rejection
      • Assessment by Target
        • Table Figure 39: Number of Products by Top 10 Targets, Kidney Transplant Rejection
        • Table Figure 40: Number of Products by Stage and Top 10 Targets, Kidney Transplant Rejection
        • Table Number of Products by Stage and Target, Kidney Transplant Rejection
      • Assessment by Mechanism of Action
        • Table Figure 41: Number of Products by Top 10 Mechanism of Actions, Kidney Transplant Rejection
        • Table Figure 42: Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Transplant Rejection
        • Table Number of Products by Stage and Mechanism of Action, Kidney Transplant Rejection
      • Assessment by Route of Administration
        • Table Figure 43: Number of Products by Routes of Administration, Kidney Transplant Rejection
        • Table Figure 44: Number of Products by Stage and Routes of Administration, Kidney Transplant Rejection
        • Table Number of Products by Stage and Route of Administration, Kidney Transplant Rejection
      • Assessment by Molecule Type
        • Table Figure 45: Number of Products by Top 10 Molecule Types, Kidney Transplant Rejection
        • Table Figure 46: Number of Products by Stage and Top 10 Molecule Types, Kidney Transplant Rejection
        • Table Number of Products by Stage and Molecule Type, Kidney Transplant Rejection
    • Lung Transplant Rejection
      • Assessment by Target
        • Table Figure 47: Number of Products by Targets, Lung Transplant Rejection
        • Table Figure 48: Number of Products by Stage and Targets, Lung Transplant Rejection
        • Table Number of Products by Stage and Target, Lung Transplant Rejection
      • Assessment by Mechanism of Action
        • Table Figure 49: Number of Products by Top 10 Mechanism of Actions, Lung Transplant Rejection
        • Table Figure 50: Number of Products by Stage and Top 10 Mechanism of Actions, Lung Transplant Rejection
        • Table Number of Products by Stage and Mechanism of Action, Lung Transplant Rejection
      • Assessment by Route of Administration
        • Table Figure 51: Number of Products by Routes of Administration, Lung Transplant Rejection
        • Table Figure 52: Number of Products by Stage and Routes of Administration, Lung Transplant Rejection
        • Table Number of Products by Stage and Route of Administration, Lung Transplant Rejection
      • Assessment by Molecule Type
        • Table Figure 53: Number of Products by Molecule Types, Lung Transplant Rejection
        • Table Figure 54: Number of Products by Stage and Molecule Types, Lung Transplant Rejection
        • Table Number of Products by Stage and Molecule Type, Lung Transplant Rejection
    • Heart Transplant Rejection
      • Assessment by Target
        • Table Figure 55: Number of Products by Targets, Heart Transplant Rejection
        • Table Figure 56: Number of Products by Stage and Targets, Heart Transplant Rejection
        • Table Number of Products by Stage and Target, Heart Transplant Rejection
      • Assessment by Mechanism of Action
        • Table Figure 57: Number of Products by Mechanism of Actions, Heart Transplant Rejection
        • Table Figure 58: Number of Products by Stage and Mechanism of Actions, Heart Transplant Rejection
        • Table Number of Products by Stage and Mechanism of Action, Heart Transplant Rejection
      • Assessment by Route of Administration
        • Table Figure 59: Number of Products by Routes of Administration, Heart Transplant Rejection
        • Table Figure 60: Number of Products by Stage and Routes of Administration, Heart Transplant Rejection
        • Table Number of Products by Stage and Route of Administration, Heart Transplant Rejection
      • Assessment by Molecule Type
        • Table Figure 61: Number of Products by Molecule Types, Heart Transplant Rejection
        • Table Figure 62: Number of Products by Stage and Molecule Types, Heart Transplant Rejection
        • Table Number of Products by Stage and Molecule Type, Heart Transplant Rejection
  • Companies Involved in Therapeutics Development
    • Bone Marrow Transplant Rejection
      • AbbVie Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by AbbVie Inc
      • AbGenomics International Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by AbGenomics International Inc
      • Actelion Ltd
        • Table Bone Marrow Transplant Rejection – Pipeline by Actelion Ltd
      • Alexion Pharmaceuticals Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Alexion Pharmaceuticals Inc
      • Allergan Plc
        • Table Bone Marrow Transplant Rejection – Pipeline by Allergan Plc
      • Amunix Operating Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Amunix Operating Inc
      • AnaptysBio Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by AnaptysBio Inc
      • apceth Biopharma GmbH
        • Table Bone Marrow Transplant Rejection – Pipeline by apceth Biopharma GmbH
      • Aptevo Therapeutics Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Aptevo Therapeutics Inc
      • arGEN-X BV
        • Table Bone Marrow Transplant Rejection – Pipeline by arGEN-X BV
      • Athersys Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Athersys Inc
      • Bellicum Pharmaceuticals Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Bellicum Pharmaceuticals Inc
      • Bio-Cancer Treatment International Ltd
        • Table Bone Marrow Transplant Rejection – Pipeline by Bio-Cancer Treatment International Ltd
      • Biogen Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Biogen Inc
      • Bristol-Myers Squibb Company
        • Table Bone Marrow Transplant Rejection – Pipeline by Bristol-Myers Squibb Company
      • Cantex Pharmaceuticals Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Cantex Pharmaceuticals Inc
      • Capricor Therapeutics Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Capricor Therapeutics Inc
      • Cell Source Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Cell Source Inc
      • Cell2B Advanced Therapeutics SA
        • Table Bone Marrow Transplant Rejection – Pipeline by Cell2B Advanced Therapeutics SA
      • CellECT Bio Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by CellECT Bio Inc
      • Cleveland BioLabs Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Cleveland BioLabs Inc
      • Compugen Ltd
        • Table Bone Marrow Transplant Rejection – Pipeline by Compugen Ltd
      • Cynata Therapeutics Limited
        • Table Bone Marrow Transplant Rejection – Pipeline by Cynata Therapeutics Limited
      • Cytodyn Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Cytodyn Inc
      • Dompe Farmaceutici SpA
        • Table Bone Marrow Transplant Rejection – Pipeline by Dompe Farmaceutici SpA
      • Dr. Falk Pharma GmbH
        • Table Bone Marrow Transplant Rejection – Pipeline by Dr. Falk Pharma GmbH
      • Escape Therapeutics Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Escape Therapeutics Inc
      • F. Hoffmann-La Roche Ltd
        • Table Bone Marrow Transplant Rejection – Pipeline by F. Hoffmann-La Roche Ltd
      • Fate Therapeutics Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Fate Therapeutics Inc
      • Generon (Shanghai) Corp Ltd
        • Table Bone Marrow Transplant Rejection – Pipeline by Generon (Shanghai) Corp Ltd
      • Gilead Sciences Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Gilead Sciences Inc
      • GlaxoSmithKline Plc
        • Table Bone Marrow Transplant Rejection – Pipeline by GlaxoSmithKline Plc
      • Immunomedics Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Immunomedics Inc
      • Incyte Corp
        • Table Bone Marrow Transplant Rejection – Pipeline by Incyte Corp
      • Jazz Pharmaceuticals Plc
        • Table Bone Marrow Transplant Rejection – Pipeline by Jazz Pharmaceuticals Plc
      • Kadmon Corp LLC
        • Table Bone Marrow Transplant Rejection – Pipeline by Kadmon Corp LLC
      • Kamada Ltd
        • Table Bone Marrow Transplant Rejection – Pipeline by Kamada Ltd
      • Kiadis Pharma NV
        • Table Bone Marrow Transplant Rejection – Pipeline by Kiadis Pharma NV
      • Kymab Ltd
        • Table Bone Marrow Transplant Rejection – Pipeline by Kymab Ltd
      • Kyorin Pharmaceutical Co Ltd
        • Table Bone Marrow Transplant Rejection – Pipeline by Kyorin Pharmaceutical Co Ltd
      • MacroGenics Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by MacroGenics Inc
      • Mallinckrodt Plc
        • Table Bone Marrow Transplant Rejection – Pipeline by Mallinckrodt Plc
      • Medsenic
        • Table Bone Marrow Transplant Rejection – Pipeline by Medsenic
      • Mesoblast Ltd
        • Table Bone Marrow Transplant Rejection – Pipeline by Mesoblast Ltd
      • Millennium Pharmaceuticals Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Millennium Pharmaceuticals Inc
      • Nektar Therapeutics
        • Table Bone Marrow Transplant Rejection – Pipeline by Nektar Therapeutics
      • Neovii Pharmaceuticals AG
        • Table Bone Marrow Transplant Rejection – Pipeline by Neovii Pharmaceuticals AG
      • Nohla Therapeutics Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Nohla Therapeutics Inc
      • Novartis AG
        • Table Bone Marrow Transplant Rejection – Pipeline by Novartis AG
      • OncoImmune Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by OncoImmune Inc
      • OSE Immunotherapeutics
        • Table Bone Marrow Transplant Rejection – Pipeline by OSE Immunotherapeutics
      • Pfizer Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Pfizer Inc
      • Pharmicell Co Ltd
        • Table Bone Marrow Transplant Rejection – Pipeline by Pharmicell Co Ltd
      • Pluristem Therapeutics Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Pluristem Therapeutics Inc
      • REGiMMUNE Corp
        • Table Bone Marrow Transplant Rejection – Pipeline by REGiMMUNE Corp
      • Sanofi
        • Table Bone Marrow Transplant Rejection – Pipeline by Sanofi
      • Sarepta Therapeutics Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Sarepta Therapeutics Inc
      • Seattle Genetics Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Seattle Genetics Inc
      • Seres Therapeutics Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Seres Therapeutics Inc
      • Sigmoid Pharma Ltd
        • Table Bone Marrow Transplant Rejection – Pipeline by Sigmoid Pharma Ltd
      • Synedgen Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Synedgen Inc
      • Taiga Biotechnologies Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Taiga Biotechnologies Inc
      • Takeda Pharmaceutical Company Ltd
        • Table Bone Marrow Transplant Rejection – Pipeline by Takeda Pharmaceutical Company Ltd
      • Targazyme Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Targazyme Inc
      • United BioPharma Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by United BioPharma Inc
      • Vault Pharma Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by Vault Pharma Inc
      • VBI Vaccines Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by VBI Vaccines Inc
      • Xenikos BV
        • Table Bone Marrow Transplant Rejection – Pipeline by Xenikos BV
      • XL-protein GmbH
        • Table Bone Marrow Transplant Rejection – Pipeline by XL-protein GmbH
      • ZIOPHARM Oncology Inc
        • Table Bone Marrow Transplant Rejection – Pipeline by ZIOPHARM Oncology Inc
    • Graft Versus Host Disease (GVHD)
      • AbbVie Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by AbbVie Inc
      • AbGenomics International Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by AbGenomics International Inc
      • Allergan Plc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Allergan Plc
      • Amunix Operating Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Amunix Operating Inc
      • AnaptysBio Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by AnaptysBio Inc
      • apceth Biopharma GmbH
        • Table Graft Versus Host Disease (GVHD) –Pipeline by apceth Biopharma GmbH
      • Aptevo Therapeutics Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Aptevo Therapeutics Inc
      • arGEN-X BV
        • Table Graft Versus Host Disease (GVHD) –Pipeline by arGEN-X BV
      • Athersys Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Athersys Inc
      • Bellicum Pharmaceuticals Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Bellicum Pharmaceuticals Inc
      • Bio-Cancer Treatment International Ltd
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Bio-Cancer Treatment International Ltd
      • Biogen Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Biogen Inc
      • Bristol-Myers Squibb Company
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Bristol-Myers Squibb Company
      • Capricor Therapeutics Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Capricor Therapeutics Inc
      • Cell2B Advanced Therapeutics SA
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Cell2B Advanced Therapeutics SA
      • CellECT Bio Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by CellECT Bio Inc
      • Commence Bio Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Commence Bio Inc
      • Cynata Therapeutics Ltd
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Cynata Therapeutics Ltd
      • Cytodyn Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Cytodyn Inc
      • Dr. Falk Pharma GmbH
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Dr. Falk Pharma GmbH
      • Escape Therapeutics Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Escape Therapeutics Inc
      • F. Hoffmann-La Roche Ltd
        • Table Graft Versus Host Disease (GVHD) –Pipeline by F. Hoffmann-La Roche Ltd
      • Fate Therapeutics Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Fate Therapeutics Inc
      • Generon (Shanghai) Corp Ltd
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Generon (Shanghai) Corp Ltd
      • Gilead Sciences Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Gilead Sciences Inc
      • GlaxoSmithKline Plc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by GlaxoSmithKline Plc
      • Incyte Corp
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Incyte Corp
      • Jazz Pharmaceuticals Plc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Jazz Pharmaceuticals Plc
      • Kadmon Corp LLC
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Kadmon Corp LLC
      • Kamada Ltd
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Kamada Ltd
      • Kiadis Pharma NV
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Kiadis Pharma NV
      • Kymab Ltd
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Kymab Ltd
      • Kyorin Pharmaceutical Co Ltd
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Kyorin Pharmaceutical Co Ltd
      • MacroGenics Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by MacroGenics Inc
      • Mallinckrodt Plc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Mallinckrodt Plc
      • Mesoblast Ltd
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Mesoblast Ltd
      • Millennium Pharmaceuticals Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Millennium Pharmaceuticals Inc
      • Nektar Therapeutics
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Nektar Therapeutics
      • Nohla Therapeutics Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Nohla Therapeutics Inc
      • Novartis AG
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Novartis AG
      • OncoImmune Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by OncoImmune Inc
      • OSE Immunotherapeutics
        • Table Graft Versus Host Disease (GVHD) –Pipeline by OSE Immunotherapeutics
      • Pfizer Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Pfizer Inc
      • Pharmicell Co Ltd
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Pharmicell Co Ltd
      • REGiMMUNE Corp
        • Table Graft Versus Host Disease (GVHD) –Pipeline by REGiMMUNE Corp
      • Sanofi
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Sanofi
      • Sarepta Therapeutics Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Sarepta Therapeutics Inc
      • Seattle Genetics Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Seattle Genetics Inc
      • Seres Therapeutics Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Seres Therapeutics Inc
      • Sigmoid Pharma Ltd
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Sigmoid Pharma Ltd
      • Synedgen Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Synedgen Inc
      • Takeda Pharmaceutical Company Ltd
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Takeda Pharmaceutical Company Ltd
      • Targazyme Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Targazyme Inc
      • TC BioPharm Ltd
        • Table Graft Versus Host Disease (GVHD) –Pipeline by TC BioPharm Ltd
      • TxCell SA
        • Table Graft Versus Host Disease (GVHD) –Pipeline by TxCell SA
      • United BioPharma Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by United BioPharma Inc
      • Vault Pharma Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Vault Pharma Inc
      • VBI Vaccines Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by VBI Vaccines Inc
      • Xenikos BV
        • Table Graft Versus Host Disease (GVHD) –Pipeline by Xenikos BV
      • XL-protein GmbH
        • Table Graft Versus Host Disease (GVHD) –Pipeline by XL-protein GmbH
      • ZIOPHARM Oncology Inc
        • Table Graft Versus Host Disease (GVHD) –Pipeline by ZIOPHARM Oncology Inc
    • Liver Transplant Rejection
      • Astellas Pharma Inc
        • Table Liver Transplant Rejection – Pipeline by Astellas Pharma Inc
      • Biogen Inc
        • Table Liver Transplant Rejection – Pipeline by Biogen Inc
      • Conatus Pharmaceuticals Inc
        • Table Liver Transplant Rejection – Pipeline by Conatus Pharmaceuticals Inc
      • Dompe Farmaceutici SpA
        • Table Liver Transplant Rejection – Pipeline by Dompe Farmaceutici SpA
      • Novartis AG
        • Table Liver Transplant Rejection – Pipeline by Novartis AG
      • RedHill Biopharma Ltd
        • Table Liver Transplant Rejection – Pipeline by RedHill Biopharma Ltd
    • Kidney Transplant Rejection
      • Amgen Inc
        • Table Kidney Transplant Rejection – Pipeline by Amgen Inc
      • Angion Biomedica Corp
        • Table Kidney Transplant Rejection – Pipeline by Angion Biomedica Corp
      • Apellis Pharmaceuticals Inc
        • Table Kidney Transplant Rejection – Pipeline by Apellis Pharmaceuticals Inc
      • Astellas Pharma Inc
        • Table Kidney Transplant Rejection – Pipeline by Astellas Pharma Inc
      • Biogen Inc
        • Table Kidney Transplant Rejection – Pipeline by Biogen Inc
      • Catalyst Biosciences Inc
        • Table Kidney Transplant Rejection – Pipeline by Catalyst Biosciences Inc
      • Corline Biomedical AB
        • Table Kidney Transplant Rejection – Pipeline by Corline Biomedical AB
      • CSL Ltd
        • Table Kidney Transplant Rejection – Pipeline by CSL Ltd
      • GlaxoSmithKline Plc
        • Table Kidney Transplant Rejection – Pipeline by GlaxoSmithKline Plc
      • Grifols SA
        • Table Kidney Transplant Rejection – Pipeline by Grifols SA
      • Hansa Medical AB
        • Table Kidney Transplant Rejection – Pipeline by Hansa Medical AB
      • Kyowa Hakko Kirin Co Ltd
        • Table Kidney Transplant Rejection – Pipeline by Kyowa Hakko Kirin Co Ltd
      • Magnus Life Ltd
        • Table Kidney Transplant Rejection – Pipeline by Magnus Life Ltd
      • Noorik Biopharmaceuticals AG
        • Table Kidney Transplant Rejection – Pipeline by Noorik Biopharmaceuticals AG
      • Novartis AG
        • Table Kidney Transplant Rejection – Pipeline by Novartis AG
      • Opsona Therapeutics Ltd
        • Table Kidney Transplant Rejection – Pipeline by Opsona Therapeutics Ltd
      • OSE Immunotherapeutics
        • Table Kidney Transplant Rejection – Pipeline by OSE Immunotherapeutics
      • Pharmicell Co Ltd
        • Table Kidney Transplant Rejection – Pipeline by Pharmicell Co Ltd
      • Pharming Group NV
        • Table Kidney Transplant Rejection – Pipeline by Pharming Group NV
      • Prolong Pharmaceuticals LLC
        • Table Kidney Transplant Rejection – Pipeline by Prolong Pharmaceuticals LLC
      • Quark Pharmaceuticals Inc
        • Table Kidney Transplant Rejection – Pipeline by Quark Pharmaceuticals Inc
      • Shire Plc
        • Table Kidney Transplant Rejection – Pipeline by Shire Plc
      • Tiziana Life Sciences Plc
        • Table Kidney Transplant Rejection – Pipeline by Tiziana Life Sciences Plc
    • Lung Transplant Rejection
      • Table Lung Transplant Rejection – Pipeline by Apeptico Forschung und Entwicklung GmbH
      • Dompe Farmaceutici SpA
        • Table Lung Transplant Rejection – Pipeline by Dompe Farmaceutici SpA
      • Kamada Ltd
        • Table Lung Transplant Rejection – Pipeline by Kamada Ltd
      • Novartis AG
        • Table Lung Transplant Rejection – Pipeline by Novartis AG
      • Quark Pharmaceuticals Inc
        • Table Lung Transplant Rejection – Pipeline by Quark Pharmaceuticals Inc
    • Heart Transplant Rejection
      • Astellas Pharma Inc
        • Table Heart Transplant Rejection – Pipeline by Astellas Pharma Inc
      • Heat Biologics Inc
        • Table Heart Transplant Rejection – Pipeline by Heat Biologics Inc
      • Noxxon Pharma AG
        • Table Heart Transplant Rejection – Pipeline by Noxxon Pharma AG
  • Dormant Projects
    • Bone Marrow Transplant Rejection
      • Table Bone Marrow Transplant Rejection – Dormant Projects
    • Graft Versus Host Disease (GVHD)
      • Table Graft Versus Host Disease (GVHD) –Dormant Projects
    • Liver Transplant Rejection
      • Table Liver Transplant Rejection – Dormant Projects
    • Kidney Transplant Rejection
      • Table Kidney Transplant Rejection – Dormant Projects
    • Lung Transplant Rejection
      • Table Lung Transplant Rejection – Dormant Projects
    • Heart Transplant Rejection
      • Table Heart Transplant Rejection – Dormant Projects
  • Discontinued Products
    • Bone Marrow Transplant Rejection
      • Table Bone Marrow Transplant Rejection – Discontinued Products
    • Graft Versus Host Disease (GVHD)
      • Table Graft Versus Host Disease (GVHD) –Discontinued Products
    • Liver Transplant Rejection
      • Table Liver Transplant Rejection – Discontinued Products
    • Kidney Transplant Rejection
      • Table Kidney Transplant Rejection – Discontinued Products
  • Product Development Milestones
    • Bone Marrow Transplant Rejection
      • Featured News & Press Releases
    • Graft Versus Host Disease (GVHD)
      • Featured News & Press Releases
    • Liver Transplant Rejection
      • Featured News & Press Releases
    • Kidney Transplant Rejection
      • Featured News & Press Releases
    • Lung Transplant Rejection
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report